AI drug discovery focus shifts to platforms as deals, $114M AI fund bolster Recursion’s long-term optionality
Analysis of this week’s developments in AI-driven drug discovery, focusing on Recursion Pharmaceuticals’ positioning within a rapidly evolving computational biology and synthesis landscape.